Johns Hopkins researchers have developed a new approach to one of Alzheimer's disease's biggest treatment challenges: figuring out which patients will actually benefit from psychiatric medications. The answer may lie in laboratory-grown brain tissues no bigger than a pea.
Scientists created miniature models of brain tissue using cells taken directly from people diagnosed with Alzheimer's. These organoids reproduce key biological features of the disease and can be tested with medications to predict how individual patients might respond. The findings suggest a path toward customized treatment plans based on each person's unique cellular profile.
Alzheimer's remains the most common form of dementia in the United States, affecting over 7 million Americans. While there is no cure, doctors frequently prescribe SSRIs, a class of antidepressants, to manage psychiatric symptoms like anxiety, depression, and agitation that plague nearly all patients. The problem is responses vary wildly from person to person, leaving clinicians to rely largely on trial and error.
To test their approach, the Johns Hopkins team focused on the hindbrain, a region at the brain's base that controls breathing, sleep, and heart rate. They wanted to see if miniature hindbrain models could reveal which patients might respond to escitalopram, a commonly prescribed SSRI.
From Blood Cells to Brain Tissue in a Dish
The process began with blood samples collected from participants with Alzheimer's disease and healthy controls at Johns Hopkins' NIH-funded Alzheimer's Disease Research Center. Researchers reprogrammed these blood cells back into a stem cell-like state, a technique that allows the cells to develop into any cell type in the body.
Using these induced pluripotent stem cells, the team guided them to self-organize into pea-sized clusters containing serotonin-producing neurons, essentially creating a functioning piece of hindbrain tissue. The study ultimately included hundreds of organoids representing individual patients, making it potentially one of the largest brain organoid studies conducted for Alzheimer's research.
When compared to organoids grown from healthy individuals, those derived from Alzheimer's patients showed clear differences in proteins involved in cell communication, inflammation, and disease-related pathways. More importantly, when exposed to escitalopram, some organoids mounted a strong molecular response while others showed minimal change.
In organoids that responded to the medication, levels of proteins involved in serotonin signaling and neural communication increased, exactly the pathways antidepressants target. This variation across patients offered a crucial insight: the organoid model appeared capable of predicting which patients might benefit from treatment.
The team also discovered something unexpected. The organoids released tiny particles called extracellular vesicles that carry cellular information. These particles proved rich with disease-relevant proteins and showed distinct changes after medication exposure. Some contained lower levels of critical proteins like RAB3A, NSF, and ATCAY, which normally help neurons communicate. After treatment with escitalopram, certain protein levels increased, especially those connected to serotonin pathways.
The variation in how different organoid samples responded suggested these vesicles could eventually serve as a liquid biopsy, potentially allowing doctors to diagnose Alzheimer's, assess disease progression, and match patients to the drugs most likely to help them.
Study leader Vasiliki Machairaki, an associate professor of genetic medicine at Johns Hopkins, emphasized that the work represents an early step. She plans to develop more sophisticated organoids that include immune cells and blood vessel networks to better mirror actual human brain tissue.
The research was published in Alzheimer's and Dementia: The Journal of the Alzheimer's Association and received funding from the National Institutes of Health, the Paul G. Allen Frontiers Foundation, and the Richman Family Precision Medicine Center of Excellence in Alzheimer's Disease.
Author Jessica Williams: "If this pans out, doctors could finally stop guessing which Alzheimer's patients will tolerate antidepressants and actually predict outcomes before writing a prescription."
Comments